開示日時：2022/04/05 19:00:00
損益
| 決算期 | 売上高 | 営業益 | 経常益 | EPS |
| 2018.03 | 22,494,200 | 3,869,100 | 3,869,100 | 86.42 |
| 2019.03 | 23,402,600 | 4,509,800 | 4,509,800 | 78.43 |
| 2020.03 | 24,155,500 | 3,353,500 | 3,353,500 | 59.01 |
| 2021.03 | 24,960,500 | 1,291,600 | 1,291,600 | 17.06 |
※金額の単位は［万円］
株価
| 前日終値 | 50日平均 | 200日平均 | 実績PER | 予想PER |
| 1,432.0 | 1,478.26 | 1,519.95 | 75.77 | 16.28 |
※金額の単位は［円］
キャッシュフロー
| 決算期 | フリーCF | 営業CF |
| 2018.03 | 3,290,600 | 4,284,300 |
| 2019.03 | 2,456,100 | 3,289,400 |
| 2020.03 | 3,071,900 | 3,994,700 |
| 2021.03 | 1,500,400 | 3,880,800 |
※金額の単位は［万円］
▼テキスト箇所の抽出
April 5, 2022 Santen Announces Change of Major Shareholder Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Shigeo Taniuchi; hereafter, the Company) hereby announces that a major shareholder of the Company has changed on March 29, 2022 as below. 1. Background of the Changes The Company has confirmed the change of holding shares of a major shareholder based on the Large Shareholding Report (Change Report) submitted by the shareholder below to the Kanto Local Finance Bureau on April 5, 2022. 2. Description of Shareholder (1) Name of shareholder (2) Address (3) Representative (4) Description of business Investment management business 3. Number and Percentage of Voting Rights owned by the Shareholder 111 Huntington Avenue, Boston, Massachusetts, 02199 U.S.A. Michael W. Roberge, Chair and Chief Executive Officer Massachusetts Financial Services Company Before After Voting rights owned by Percentage of Shareholder Shareholder outstanding shares ranking 432,079 391,201 10.80% 9.77% – – (as of December 10, 2021) (43,207,950 shares) (as of April 5, 2022) (39,120,165 shares) Note1. The above is written on the basis of the Large Shareholding Report (Change Report) submitted by the shareholder in question. It does not represent confirmation by the Company of the actual number of shares held in the name of the shareholder in question. The ranking of major shareholders has not been confirmed, and therefore is not indicated here. Note 2. Percentage of total shareholder voting rights is calculated based on the total number of shares issued and outstanding as of February 28, 2022, which is 400,664,754 shares less the number of shares not subject to voting rights of 407,397 shares, which is 4,002,573 of total shareholder voting rights. Percentage of total shareholder voting rights is rounded to the nearest third decimal place. 4. Outlook for the Future Nothing in particular. Contact: Guillaume Sakuma Global Head of IR, IR Group E-mail: ir@santen.com About Santen As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries. Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen’s website ( https://www.santen.com/en/ ).
